🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Stephens rates Exelixis stock as overweight; highlights Cabo franchise

EditorIsmeta Mujdragic
Published 05/14/2024, 11:44 AM
EXEL
-

On Tuesday, Stephens initiated coverage on Exelixis (NASDAQ:EXEL), a biotechnology company traded under NASDAQ:EXEL, with an Overweight rating and a price target of $23.00. The firm's analyst pointed to the success of the CABOMETYX (Cabo) franchise, which has become a multi-billion dollar asset in the competitive renal cell carcinoma (RCC) market.

Despite the success of CABOMETYX, the firm has expressed caution due to the potential challenges ahead. The drug is nearing its loss of exclusivity in the RCC market, which is already saturated and highly competitive. There is also the risk of accelerated loss of exclusivity due to ongoing ANDA litigation, which could potentially shorten the drug's market exclusivity period.

The firm noted that they will remain on the sidelines until they have more clarity on the outcome of the ANDA litigation and advancements in Exelixis's pipeline. The results of the ANDA litigation trial are expected in the first half of 2024, which could be a near-term catalyst for the stock.

Additionally, the progress of clinical trials for Cabo, as well as other pipeline assets that may lead to filing for label expansion and entering new markets, are also anticipated to influence the company's valuation.

Investors and market watchers are now looking forward to the outcomes of the ongoing litigation and clinical trials, which are expected to provide further direction for Exelixis's stock performance.

InvestingPro Insights

As Exelixis navigates the competitive landscape of the RCC market and the uncertainties surrounding its flagship CABOMETYX franchise, real-time data from InvestingPro provides a comprehensive view of the company's financial health. With a market capitalization of $6.2 billion and a P/E ratio adjusted for the last twelve months as of Q1 2024 standing at 26.75, Exelixis appears to be trading at a valuation that reflects its near-term earnings potential. Moreover, the company's revenue growth of nearly 11% over the last twelve months signals its ability to expand even in a challenging environment.

InvestingPro Tips highlight several key factors that could influence investor sentiment. Notably, Exelixis's management has been actively repurchasing shares, signaling confidence in the company's future. Additionally, the company's solid financial position is underscored by its cash reserves exceeding its debt, and its high shareholder yield. These factors, combined with the 7 analysts who have revised their earnings upwards for the upcoming period, suggest that Exelixis may be well-positioned for future growth.

While the company does not pay a dividend, which may deter income-focused investors, its high return over the last decade could appeal to those seeking long-term capital appreciation. For those interested in delving deeper, there are 12 additional InvestingPro Tips available at https://www.investing.com/pro/EXEL, providing further insights into Exelixis's performance and prospects. To access these valuable tips, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.